- CE mark of these next-generation cardiac imaging systems will
further enable connected care along the cardiology patient journey
and provide clinicians with the tools to deliver more efficient and
timely care
Today, GE HealthCare (Nasdaq: GEHC) announced the CE marks of
its Vscan Air™ SL wireless handheld ultrasound system with Caption
AI™ (Vscan Air SL with Caption AI), an artificial intelligence
(AI)-driven software for rapid cardiac assessments at the point of
care, as well as ECG-less Cardiac computed tomography (CT) scanning
on its Revolution Apex™ platform, which allows clinicians to
acquire cardiac images without the aid of the patients’
electrocardiogram (ECG) signal/trace. Both technologies will be
showcased at the European Society of Cardiology (ESC) Congress, in
London, August 30-September 2, 2024.
Cardiovascular diseases are the leading cause of death globally,
claiming an estimated 17.9 million lives each year. There is an
urgent need to diagnose cardiovascular disease earlier to help curb
cardiac deaths across the world as more than 60% of these deaths
are preventable and premature.1,2 In order to meet this challenge,
clinicians across various care areas need the best possible tools
and technologies to diagnose and treat cardiovascular disease more
efficiently to enable better patient outcomes.
GE HealthCare will showcase its latest technology that brings
high-quality imaging to the patient’s bedside, cardiac
catheterization laboratory and other hospital settings. The
ultraportable Vscan Air SL with Caption AI is designed to help more
healthcare professionals capture cardiac images so that even
non-experts in cardiac ultrasound can help tell the story of their
patients’ hearts, better informing diagnoses and treatment plans.
Access to this novel technology enables earlier heart disease
detection and expands cardiac care into primary care and emergency
settings. Vscan Air SL with Caption AI can provide real-time,
step-by-step visual guidance to optimize probe movements and
includes a quality meter to ensure the user obtains the best
possible images. Once a user captures an image, the AutoEF
(ejection fraction) feature automatically calculates a left
ventricular ejection fraction (LVEF), an important measure of heart
function.
During the ESC Congress, three dedicated educational tutorials
will be held on-site for Vscan Air SL with Caption AI, including
live scanning demonstrations. Find out more here.
“With diseases of the heart and blood vessels representing
nearly one-third of all global deaths, innovation within cardiac
diagnostics and treatment is one of our top priorities as a
healthcare company,” said Phil Rackliffe, president and CEO of
Ultrasound and Image Guided Therapies, GE HealthCare. “The
integration of Caption AI on Vscan Air SL is a major step toward
helping more users confidently capture diagnostic-quality images to
inform clinical decisions when time is of the essence. With the
recent CE mark, we’re eager to bring this technology to more
healthcare providers around the world.”
GE HealthCare will also be showcasing the recently CE marked and
U.S. FDA cleared ECG-less Cardiac CT solution, which can acquire
cardiac images without the aid of the patients’ ECG signal/trace.
This technology is applied in examinations where it is clinically
advantageous to prioritize patient access or speed when the ECG
signal is unavailable. ECG-less Cardiac CT scanning is exclusively
available on and further enhances the capabilities of the company’s
Revolution Apex Elite, which already boasts a 160mm detector
configuration and the ability to achieve one-beat, high definition,
motion-free coronary images at any heart rate. This system is
available as a part of GE HealthCare’s broader Revolution Apex
platform, a world class scalable CT solution that offers modern
computed tomography (CT) technology to provide versatile clinical
solutions for even the most challenging patients.
The advanced technology is further enhanced with Effortless
Workflow, which intelligently automates the CT workflow from
pre-scan protocoling to post-scan processing, using AI-based
features to help transform the entire CT experience and provide
optimal efficiency, accuracy, clarity and consistency. This enables
technologists to personalize scans automatically and accurately for
each patient with significantly less effort. The results are high
quality CT images acquired more quickly and efficiently: 56%
reduction in positioning time3; 66% reduction in total exam
clicks4; and 21% reduction in total exam time5.
“Providing rapid, flexible and at the point of care cardiac
diagnostics is critical in terms of patient outcomes – however,
timely care can be extremely difficult to deliver, particularly
within already-stretched healthcare systems where clinicians face
time and resource constraints,” said Eigil Samset, general manager,
Cardiology Solutions, GE HealthCare. “Through our innovative
cardiology solutions and by leveraging the power of AI, we aim to
address these challenges and help clinicians understand the
complete story of their patients’ hearts as quickly as possible. I
am thrilled that this suite of integrated cardiac care solutions is
now accessible to more providers so that they are able to deliver
efficient and timely patient care when and where it is needed
most.”
Building on the recent CE marks, these innovative cardiology
solutions will be on display at GE HealthCare Booth # F400 South in
a fully functional cardiac catheterization laboratory at ESC
Congress 2024. The lab will showcase the company’s latest image
guided platform Allia™ IGS 5 Pulse, designed to improve workflow
for the diagnosis and treatment of cardiovascular diseases in
interventional cardiology, as well as feature INTERACT Touch with
AVVIGO+™ Multi-Modality Guidance System from Boston Scientific6 -
the first third party application available with this
technology.
To learn more about the GE HealthCare solutions that will be
showcased on-site at ESC Congress 2024 or to register for one of
the 33 tutorial sessions and live demonstrations sponsored by the
company, please visit
https://events.gehealthcare.com/events/esc-2024/.
Forward-Looking Statements
This release contains forward-looking statements. These
forward-looking statements might be identified by words, and
variations of words, such as “will,” “expect,” “may,” “would,”
“could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,”
“potential,” “position,” “forecast,” “target,” “guidance,”
“outlook,” and similar expressions. These forward-looking
statements may include, but are not limited to, statements about
the transaction, the completion and expected results of the
transaction, and GE HealthCare Technologies Inc.’s (the
“Company’s”) performance, growth opportunities, and strategy. These
forward-looking statements involve risks and uncertainties, many of
which are beyond the control of the Company. Factors that could
cause the Company’s actual results to differ materially from those
described in its forward-looking statements include, but are not
limited to, the conditions to the completion of the transaction may
not be satisfied; closing of the transaction may not occur or may
be delayed; the Company may be unable to achieve the anticipated
benefits of the transaction; operating costs and business
disruptions (including, without limitation, difficulties in
maintaining relationships with employees, customers, and suppliers)
may be greater than expected; the Company may assume unexpected
risks and liabilities; and completing the transaction may distract
the Company’s management from other important matters. Other
factors that may cause such a difference also include those
discussed in the "Risk Factors" section of the Company’s Annual
Report on Form 10-K filed with the U.S. Securities and Exchange
Commission and any updates or amendments it makes in future
filings. There may be other factors not presently known to the
Company or which it currently considers to be immaterial that could
cause the Company’s actual results to differ materially from those
projected in any forward-looking statements the Company makes. The
Company does not undertake any obligation to update or revise its
forward-looking statements except as required by applicable law or
regulation.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X , Facebook, Instagram, and Insights for
the latest news, or visit our website https://www.gehealthcare.com/
for more information.
____________________
1 World Health Organization.
Cardiovascular diseases (CVDs). June 11, 2021. Available at:
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
Accessed July 2024.
2 Vaduganathan M, Mensah G, Turco J, et
al. The Global Burden of Cardiovascular Diseases and Risk: A
Compass for Future Health. JACC. 2022;80(25):2361-2371.
https://doi.org/10.1016/j.jacc.2022.11.005
3 The data was based on comparison between
GE HealthCare’s legacy products (16 ch and 64 ch scanner) and
Revolution Ascend in the three institutions using a pilot product
and selected routine head and body. The data set of this comparison
was 838 exams for legacy products and 1387 exams for Revolution
Ascend. The time saving value may not be effective for all
institutions depending on the clinical practice. Defined the scan
setting time is from “Open new patient” to “Confirm setting for
Scout”
4 The required clicks are defined as
clicks required to execute a scan from selecting a new patient till
start scan. All associated clicks for and in clinical practice,
number of the required clicks may vary depending on the
circumstances, including but not limited to, the clinical task,
exam type, clinical practice, and image reconstruction
technique.
5 The data was based on comparison between
GE HealthCare’s legacy products (16 ch and 64 ch scanner) and
Revolution Ascend in the three institutions using a pilot product
and selected routine head and body. The data set of this comparison
was 838 exams for legacy products and 1387 exams for Revolution
Ascend. The time saving value may not be effective for all
institutions depending on the clinical practice. Definition of
entire exam time is from “Open new patient” to “Last primary recon
completed” for Revolution Ascend and “Close exam” for legacy
products.
6 INTERACT Touch with AVVIGO+ is pending
CE Mark and not available for sale.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240826680336/en/
GE HealthCare Media Contact Karin Dalsin Global
Communications Director karin.dalsin@gehealthcare.com
+1-612-219-2855
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Nov 2024 to Dec 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Dec 2023 to Dec 2024
